Edition:
United Kingdom

AxoGen Inc (AXGN.OQ)

AXGN.OQ on NASDAQ Stock Exchange Capital Market

20.19USD
22 Apr 2019
Change (% chg)

-- (--)
Prev Close
$20.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
218,597
52-wk High
$56.75
52-wk Low
$14.13

Latest Key Developments (Source: Significant Developments)

Axogen Says Recon Study Will Support Submission Of Biologic License Application To FDA For Avance Nerve Graft
Monday, 22 Apr 2019 

April 22 (Reuters) - AxoGen Inc ::AXOGEN, INC. ANNOUNCES COMPLETION OF PLANNED INTERIM ANALYSIS AND ONE-TIME ENROLLMENT EXPANSION FOR RECON® STUDY.AXOGEN INC - STUDY WILL SUPPORT SUBMISSION OF A BIOLOGIC LICENSE APPLICATION (BLA) TO FDA FOR AVANCE NERVE GRAFT.AXOGEN INC - STUDY ENROLLMENT TARGET WILL BE INCREASED BY 50 SUBJECTS TO A TOTAL TARGET OF 220 SUBJECTS.AXOGEN INC - EXPECTS TO COMPLETE ENROLLMENT DURING SUMMER OF 2020.  Full Article

Axogen Inc Reports Fourth Quarter Results
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - AxoGen Inc ::AXOGEN, INC. REPORTS 2018 FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 ADJUSTED LOSS PER SHARE $0.09.Q4 LOSS PER SHARE $0.13.SEES FY 2019 REVENUE $109 MILLION TO $114 MILLION.Q4 REVENUE ROSE 38 PERCENT TO $23.4 MILLION.REITERATES ITS EXPECTATION FOR GROSS MARGIN TO REMAIN ABOVE 80% FOR 2019.  Full Article

Axogen Inc Reiterates Financial Guidance for 2018 and 2019
Monday, 19 Nov 2018 

Nov 19 (Reuters) - AxoGen Inc ::AXOGEN INC - MANAGEMENT REITERATES 2018 ANNUAL REVENUE WILL GROW AT LEAST 40% OVER 2017 REVENUE AND GROSS MARGINS WILL REMAIN ABOVE 80%.AXOGEN INC - MANAGEMENT REITERATES 2019 ANNUAL REVENUE WILL GROW AT LEAST 35% OVER 2018 REVENUE AND GROSS MARGINS WILL REMAIN ABOVE 80%.AXOGEN INC - EXPECTS TO LAUNCH AXOGUARD NERVE CAP IN SECOND HALF OF 2019.  Full Article

AxoGen Q3 Adjusted Loss Per Share $0.05
Monday, 29 Oct 2018 

Oct 29 (Reuters) - AxoGen Inc ::AXOGEN, INC. REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 ADJUSTED LOSS PER SHARE $0.05.Q3 LOSS PER SHARE $0.11.Q3 REVENUE ROSE 41 PERCENT TO $22.7 MILLION.SEES FY 2018 REVENUE UP AT LEAST 40 PERCENT.SEES FY 2019 REVENUE UP AT LEAST 35 PERCENT.REITERATES FULL YEAR 2018 GUIDANCE AND INTRODUCES 2019 GUIDANCE.  Full Article

Avance Nerve Graft Receives Regenerative Medicine Advanced Therapy Designation
Monday, 29 Oct 2018 

Oct 29 (Reuters) - AxoGen Inc ::AVANCE® NERVE GRAFT RECEIVES REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION.AXOGEN - CONTINUES TO ENROLL ITS PIVOTAL STUDY, RECON, UNDER IND PROGRAM AND ANTICIPATES ENROLLMENT TO BE COMPLETE BY END OF 2018.AXOGEN INC - FDA HAS GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION TO AVANCE® NERVE GRAFT.  Full Article

Axogen Inc Q2 Loss Per Share $0.20
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - AxoGen Inc ::AXOGEN, INC. REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS.Q2 ADJUSTED LOSS PER SHARE $0.09.Q2 LOSS PER SHARE $0.20.Q2 REVENUE ROSE 36 PERCENT TO $20.6 MILLION.SEES FY 2018 REVENUE UP AT LEAST 40 PERCENT.  Full Article

Axogen Inc Says On May 15, Board Elected CEO Zaderej To Succeed Grooms As Chairman
Friday, 18 May 2018 

May 18 (Reuters) - AxoGen Inc ::AXOGEN INC SAYS ON MAY 15, BOARD ELECTED CEO KAREN ZADEREJ TO SUCCEED JAMIE GROOMS AS CHAIRMAN OF BOARD - SEC FILING.  Full Article

AxoGen Upsizes Public Offering To 3 Mln Shares At $41 Per Share
Wednesday, 9 May 2018 

May 9 (Reuters) - AxoGen Inc ::AXOGEN, INC. ANNOUNCES UPSIZING AND PRICING OF PUBLIC OFFERING OF COMMON STOCK.AXOGEN INC - PRICED PUBLIC OFFERING OF 3 MILLION SHARES WHICH WAS UPSIZED FROM PREVIOUSLY ANNOUNCED 2 MILLION SHARES, AT A PRICE OF $41.00 PER SHARE.  Full Article

AxoGen Announces Proposed Public Offering Of Common Stock
Monday, 7 May 2018 

May 7 (Reuters) - AxoGen Inc ::AXOGEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AXOGEN INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 2 MILLION SHARES OF ITS COMMON STOCK.AXOGEN INC - INTENDS TO USE NET PROCEEDS FROM PROPOSED OFFERING FOR LONG TERM FACILITY AND CAPACITY EXPANSION AND GENERAL CORPORATE PURPOSES.  Full Article

AxoGen Reports Q1 Loss Per Share Of $0.16
Monday, 30 Apr 2018 

April 30 (Reuters) - AxoGen Inc ::AXOGEN, INC. REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS.Q1 ADJUSTED LOSS PER SHARE $0.11.Q1 LOSS PER SHARE $0.16.Q1 REVENUE ROSE 41 PERCENT TO $17.3 MILLION.SEES FY 2018 REVENUE UP AT LEAST 40 PERCENT.FY2018 REVENUE VIEW $84.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article